header-images_Technology.png

Our Technology

Personalized treatment for cancer is a major medical breakthrough. But, determining which drug will prove most effective for each patient remains a major challenge. Curesponse has developed cResponse, a 3D functional drug-selection assay, which evaluates tumor sensitivity to cancer drugs. The platform, preserves the cancer tissue (including vasculature and immune system) accurately reflecting the cancer growth found in the body. The tissue can be grown ex vivo for up to 10 days, enabling genomic assessment prior to functional drug selection. By using combined genomic drug selection and functional testing, cResponse provides the most accurate drug recommendations for the patient.

The cResponse™ platform

cResponse™ offers a significant advantage over personalized cancer technologies and tests currently available in the market. We provide a functional read out of the drug effect on the patient’s tumor in the context of the microenvironment.

 

The cResponse™ personalized cancer test provides:

  • Accurate genomic report and drug prioritization within 2 weeks

  • Reliable selection of drugs before they are administered

  • Recommendation of the most efficient therapy for each patient

The cResponse™ Advantage

The clinical importance

of the tumor microenvironment

The development of effective anti-cancer drugs is complicated by the overall complexity of tumors. It is well established that the response of cancer cells to therapeutics is significantly affected by their microenvironment. Certain drugs may demonstrate high efficacy when tested on cancer cells in vitro. However in vivo, different factors in the Tumor Micro Environment (TME), will result in tumor drug resistance.

 

In addition, major events occurring in the TME (for example, response to hypoxia, extra cellular matrix composition alternations, immune cells response, etc.), support tumor growth and progression. These factors significantly influence the efficacy of drugs and are themselves drug targets. The cResponse platform preserves cancer tissue in its microenvironment thereby maximizing the accuracy of predicting drug response. 

cResponse™ is a proprietary system which allows for a long-term 3D cell culture with extremely high viability and tissue preservation. As can be seen in the images below, even after 10 days in culture, colorectal cancer maintains an identical structure to earlier morphology. Extended tissue culture time is important since many drugs require several days in culture to achieve their maximal efficacy.

Long Term EVOC

Maintaining Extended Tissue Viability

1. Drug selection by physician & genomics

2. Cancer sample

removed from patient

3. 3D tissue culture system

4. Evaluation by a pathologist

Caution: Investigational Technology. Not yet approved by Federal (or United States) Law to Clinical Use.

© 2018 All rights reserved to Curesponse

Website by: Anat Belinson

Curesponse logo